Part-Time

Senior Quality Assurance Auditor

Healx

Healx

51-200 employees

AI-driven drug discovery for rare diseases

No salary listed

Cambridge, UK

Hybrid

Hybrid role based in Cambridge, United Kingdom; occasional travel to the United States (1-2 times/year).

Bachelor's

Category
QA & Testing (1)

Get referred to Healx

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Science, Life Science or Health related field, or in Quality Management
  • Deep understanding of ICH-GCP and GMP guidelines, working knowledge of applicable EU directives/regulations, UK legislation and international clinical trial regulations (e.g., EU GMP, US FDA cGMP)
  • Strong analytical, problem-solving, and decision-making abilities
  • Process oriented and pragmatic
  • Excellent communication and interpersonal skills for leading teams and stakeholders
  • Willingness to travel to the US (once or twice a year)
  • Hands-on and collaborative approach to strong analytical, problem-solving
  • Interest in biotech/ techbio and its impact of improving patient outcomes
  • Experience with electronic Quality Management Systems (eQMS) is a bonus
  • Ability to work in cleanroom environments and experience of conducting GMP audits is a bonus
Responsibilities
  • Review and co-approve Quality Technical Agreements with GMP vendors, and ensure any project study changes in scope are appropriately reflected
  • Manage GMP documents, review and co-approve batch records, and ensure proper control and archiving of quality-related data
  • Work closely with Regulatory Affairs to ensure that all manufacturing and clinical activities remain in strict alignment with current regulatory filings (e.g., IND, CTA, or MAA) and to support the preparation of regulatory submissions
  • Product Release: Approve or reject raw materials, intermediates, and finished products, often involving data review and certification. Verify that batch documentation and product specifications comply with the 'Approved' versions filed with Health Authorities before final certification or release
  • Investigations: Investigate out-of-specification (OOS) results, deviations, and trends, performing root cause analysis (RCA)
  • Include-Represent QA as needed for any product complaints and on the SPEC Committee
  • Work closely with 3rd party Production, R&D, QC, and Supply Chain teams and Regulatory Affairs teams to ensure chemistry, manufacturing, and control (CMC) compliance
  • Develop, write and maintain company SOPs in accordance with industry expectations, ICH-GCP and GMP guidelines and regulations where Healx operates
  • Maintain and improve Healx’s Quality Management System (QMS), including delivery of training and tracking of training across company, change control (including regulatory impact assessment in coordination with Regulatory Affairs), deviations, CAPAs, and risk assessments, in cooperation with the management team (MT), department directors and with support from the Clinical Team
  • Prepare and execute the annual audit plan (scope to include compliance with QMS, external audits at investigational sites and third-party vendors) and in ensuring vendors maintain their qualification
  • Ensure Healx is inspection ready at all times and conduct self-inspections and advise the Management Team and department directors on vendor selection and evaluation process
  • Liaise with Regulatory Affairs as the primary point of contact for official Health Authority inspections (e.g., MHRA, FDA, EMA), ensuring coordinated communication and timely submission of responses to inspection findings
  • Manage and oversee third party auditors to ensure compliance with Healx’s audit standards and current guidelines
  • Assist in the preparation, management, hosting and follow-up of audits/inspections by third parties
  • Provide recommendations for corrective and preventive actions (CAPAs) resulting from audits and provide advice on the resolution of any other quality-related issues, escalations
  • Assist the Clinical team in preparing a project-specific Risk Management Plan.
  • Assist the Clinical team in preparing risk-based monitoring plans
  • Train personnel on Risk Management as appropriate
  • Have successfully managed the interface between Quality and Regulatory Affairs, specifically regarding the regulatory impact of manufacturing changes and clinical trial amendments
  • Have ensured that audit results are monitored for trends and advise the Leadership Team, and staff, on improvements
  • Sucessfully assisted the Leadership Team in preparing and maintaining a corporate Risk Management Plan (RMP)
  • Have translated guidelines, rules and regulations into clear and usable recommendations / procedures
Desired Qualifications
  • Experience with electronic Quality Management Systems (eQMS)
  • Ability to work in cleanroom environments and experience of conducting GMP audits

Healx uses artificial intelligence to discover and repurpose drugs for rare diseases. Its AI platform analyzes biomedical data to identify existing medicines that could treat rare conditions and speeds up the research and development process through collaborations with patient groups, research institutions, and pharmaceutical companies. The company then licenses or milestones its discoveries to partners, sharing royalties based on successful therapies. Unlike firms that build candidates in-house, Healx focuses on partnerships and drug repurposing to expand its pipeline and reduce time and cost of bringing treatments to patients. The overall goal is to bring safe and effective therapies to people with rare diseases more quickly and efficiently.

Company Size

51-200

Company Stage

Series C

Total Funding

$136.9M

Headquarters

Cambridge, United Kingdom

Founded

2014

Get referred to Healx

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 orphan designation for HLX-1502 strengthened pricing power and regulatory visibility.
  • February 2025 first-patient dosing in INSPIRE-NF1 de-risked the lead program.
  • The 2025 Vuja De transaction broadened Healx into rare and pediatric oncology.

What critics are saying

  • Healx depends on HLX-1502 and HLX-4310 readouts; failures crush valuation by 2027.
  • The company still lacks disclosed commercial revenue, relying on milestones, licenses, and royalties.
  • Rare-disease biotech rivals with deeper capital, like Recursion and Exscientia, outspend Healx decisively.

What makes Healx unique

  • Healx pairs AI drug discovery with patient groups like CTF and SCI Ventures.
  • Its first-in-class HLX-1502 reached Phase 2 after FDA clearance and orphan designation.
  • Vuja De Sciences added HLX-4310, giving Healx two clinical-stage oncology assets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

Life Insurance

Remote Work Options

Flexible Work Hours

Hybrid Work Options

Home Office Stipend

Paid Vacation

Paid Holidays

Wellness Program

Professional Development Budget

Community Engagement and Support

Family Planning Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Healx
Sep 22nd, 2025
Healx Strengthens Focus on Preventing Cancer Recurrence by Leveraging Its AI-Powered Platform and Advancing Its Oncology Pipeline Through a Strategic Transaction with Vuja De Sciences - Healx

Healx’s proprietary AI platform has uncovered and prioritised therapeutic opportunities across rare diseases and is actively applied in rare and pediatric oncology.  The platform is designed to generate and advance Healx’s own discovery programs, making it a natural fit with Vuja De Sciences, which brings both deep expertise in metastatic recurrence and a clinical-stage programme … Continued

Business Weekly
Jul 1st, 2025
Healx secures $2m for paralysis research

SCI Ventures, a $40m fund backed by the Christopher & Dana Reeve Foundation, has partnered with Healx, investing $2m to tackle paralysis from spinal cord injury (SCI) using AI. This collaboration aims to discover new treatments for SCI, affecting over 20 million globally. By leveraging AI and drug repurposing, the partnership seeks to accelerate therapy development, potentially impacting other CNS conditions like ALS, MS, and Alzheimer's.

Labiotech
Nov 18th, 2024
What Is Abcam’S Founder, Jonathan Milner, Up To?

Do you know who Jonathan Milner is? If you’ve ever worked in a biotech lab, chances are you’ve benefited from his legacy. The founder of Abcam, Jonathan Milner, transformed the way scientists access antibodies. Under his leadership as chief executive officer (CEO) until 2014, Abcam grew into a multinational entity with a market capitalization of approximately £3 billion.In 2023, Abcam became the subject of a $5.7 billion acquisition bid by Danaher Corporation. Jonathan Milner, holding a 6.14% stake in Abcam, publicly opposed the deal, arguing that the $24 per share offer undervalued the company. Despite his efforts, the acquisition was completed in December 2023.With his 6.14% stake in Abcam, amounting to approximately 14 million shares at the time of its acquisition by Danaher at $24.00 a share, Jonathan Milner must have received around $336 million in the process. For most, such a windfall might signal a peaceful retirement

TechCrunch
Aug 1st, 2024
Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M | TechCrunch

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding.

PR Newswire
Apr 11th, 2024
Children'S Tumor Foundation Invests In Healx To Advance Neurofibromatosis Type 1 Treatments

Milestone payments from CTF will support advance of Healx's lead compound, HLX-1502, to clinical trials and broader Neurofibromatosis Type 1 programInvestment reinforces long-term, patient-focused partnership combining Healx's proprietary AI-powered drug discovery platform with CTF's preclinical and clinical research and patient community knowledgeNEW YORK, April 11, 2024 /PRNewswire/ -- Healx , the AI-powered, patient-inspired, techbio company pioneering the next generation of drug discovery, today announced that it has signed an investment agreement with its long-term partner, Children's Tumor Foundation (CTF). Milestone-driven payments from CTF will support the advance of Healx's AI-powered neurofibromatosis program including its lead candidate, HLX-1502, which is on course to enter a Phase 2 clinical trial in the coming months.Healx has partnered with CTF since 2020 to combine its cutting-edge AI platform and drug discovery expertise in identifying novel treatments for rare diseases such as Neurofibromatosis Type 1 (NF1) with CTF's preclinical and clinical research and patient knowledge.Investment merges Healx's AI drug platform with CTF's research/patient insights, fostering a patient-centered alliance. Post thisNF1 is a rare genetic condition that causes tumours to grow along the nerves. The two most common types of tumors are plexiform and cutaneous. Currently, there is only one approved treatment, a MEK inhibitor, for a subset of patients with plexiform neurofibromas. There are no approved pharmacological treatments for patients with cutaneous neurofibromas, representing a significant unmet need for the estimated 3 million people with the disease across the globe.Identified using Healx's AI-informed approach, HLX-1502 has a novel mechanism of action, and is supported by data that suggest a favourable safety profile